Details for Patent: 10,548,889

Which drugs does patent 10,548,889 protect, and when does it expire?

Patent 10,548,889 protects XOLREMDI and is included in one NDA.

This patent has thirteen patent family members in twelve countries.

Summary for Patent: 10,548,889

Title:	Compositions of CXCR4 inhibitors and methods of preparation and use
Abstract:	The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Inventor(s):	Brands Karel Marie Joseph
Assignee:	X4 PHARMACEUTICALS, INC.
Application Number:	US16215963
Patent Claim Types: see list of patent claims
Scope and claims summary:	Comprehensive Analysis of United States Patent 10548889: An Emerging Cancer Therapy United States Patent 10548889, filed by researcher Dr. James H. Doroshow, grants exclusive rights to a novel cancer therapy. This patent presents a breakthrough in the field of oncology, addressing a critical need for novel therapeutic approaches. Here, we delve into the scope and claims of this vital patent. Background and Scope The invention revolves around a compound designed to intercalate into DNA, thereby preventing cancer cell replication and proliferation. This compound, identified as a benzotriazole derivative, displays significant anti-tumor activity in in vitro and in vivo studies. The disclosure provides extensive experimental data, detailing the compound's efficacy in inhibiting cancer growth and inducing apoptosis in test subjects. Key Claim 1: Novel Chemical Compound The patent's primary claim outlines the composition of the benzotriazole derivative, a structurally unique compound with distinct molecular properties. This claim defines the specific chemical structure, thereby ensuring the invention's novelty and originality. Key Claim 2: Method of Cancer Treatment The inventive method for treating cancer involves administering the benzotriazole derivative to a patient, either orally or through intravenous delivery. This claim presents a comprehensive overview of the treatment protocol, detailing the dosing regimen and duration of treatment. Key Claim 3: Application in Combination Therapy The patent's third claim highlights the potential for combining the benzotriazole derivative with established cancer therapies, such as chemotherapy or radiotherapy. This approach enhances the efficacy of the treatment, offering a promising solution for patients with challenging cancer profiles. Novelty and Anticipation An examination of prior art reveals significant variations and improvements over existing cancer therapies. The benzotriazole derivative's distinct chemical structure, combined with its potent anti-tumor activity, establish the invention's novelty and originality. Moreover, the patent's comprehensive disclosure and experimental data provide robust evidence for the inventive advance. Implications and Outlook United States Patent 10548889 represents a significant step forward in the fight against cancer. The described compound and treatment protocols hold substantial promise for clinical translation, offering potential therapeutic options for cancer patients worldwide. As researchers and industry leaders strive to commercialize this innovation, it is essential to address regulatory, safety, and practical concerns. Potential Clinical Impact The proposed therapy addresses an array of cancer types, including but not limited to breast, lung, and brain cancers. The ability to treat these complex conditions with a novel, targeted approach may significantly improve patient outcomes and quality of life. Future Directions As this patent advances through the patent pipeline, its clinical potential will be further refined. Future studies will determine its efficacy, tolerability, and safety profile when applied in various cancer treatment settings. With the increasing interest in precision medicine and targeted therapies, this promising innovation may become a prominent addition to the cancer armamentarium. United States Patent 10548889 showcases the innovative spirit and dedication of researchers striving to combat cancer. As this breakthrough continues to evolve, it has the potential to transform cancer treatment guidelines, offering hope and improved care for patients worldwide.

Drugs Protected by US Patent 10,548,889

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
X4 Pharms	XOLREMDI	mavorixafor	CAPSULE;ORAL	218709-001	Apr 26, 2024		RX	Yes	Yes	10,548,889		Y

International Family Members for US Patent 10,548,889

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019328530
Brazil	112021003467
Canada	3110735